Synthesis of disubstituted imidazo[4,5-b]pyridin-2-ones

Journal of Organic Chemistry

Volumn 69, Issue 22, 2004, Pages 7752-7754

  Kuethe, Jeffrey T ^a   Wong, Audrey ^a   Davies, Ian W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINATION; CATALYSIS; PALLADIUM; SUBSTITUTION REACTIONS; SYNTHESIS (CHEMICAL);

2,3-DIAMINOPYRIDINES; DISUBSTITUTION REACTIONS; PALLADIUM-CATALYZED AMINATION; REGIOSELECTIVITY;

KETONES;

2 CHLORO 3 IODOPYRIDINE; 2,3 DIAMINOPYRIDINE DERIVATIVE; IMIDAZO[4,5 B]PYRIDIN 2 ONE DERIVATIVE; IMIDAZOLE DERIVATIVE; PALLADIUM; PHOSGENE; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDO[2,3 B]PYRAZINEDIONE DERIVATIVE; THIADIAZOLE DERIVATIVE; THIADIAZOLO[3,4 B]PYRIDIN 2 ONE DERIVATIVE; TRIPHOSGENE; UNCLASSIFIED DRUG;

AMINATION; ARTICLE; CATALYST; CHEMICAL ANALYSIS; CHEMICAL REACTION; CROSS COUPLING REACTION; CYCLIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; REACTION ANALYSIS; REPRODUCIBILITY; STEREOCHEMISTRY; SUBSTITUTION REACTION; TECHNIQUE;

CHEMISTRY, ORGANIC; IMIDAZOLES; MOLECULAR STRUCTURE; PYRIDINES; PYRIDONES;

EID: 6344277027     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo048887v     Document Type: Article

References (48)

1. For a recent review on the biological activity of imidazo[4,5-b] pyridines, see: Dubey, P. K.; Kumar, R. V.; Naidu, A.; Kulkarni, S. M. Asian J. Chem. 2002, 14, 1129.
2. (a) Middleton, W. R.; Wibberley, D. G. J. Heterocycl. Chem. 1980, 17, 1757 and references therein.
3. (b) Bukowski, L.; Janowiec, M. Pharmazie 1988, 43 (H.5), 315 and references therein,
4. (c) Chakravarty, P. K.; Naylor, E. M.; Chen, A.; Chang, R. S. L.; Chen, T.; Faust, K. A.; Lotti, V. J.; Kivlighn, S. D.; Gable, R. A.; Zingaro, G. J.; Schorn, T. W.; Schaffer, L. W.; Broten, T. P.; Siegl, P. K. S.; Patchett, A. A.; Greenlee, W. J. J. Med. Chem. 1994, 37, 4068 and references therein,
5. (d) Mantlo, N. B.; Chakravarty, P. K.; Ondeyka, D. L.; Siegl, P. K. S.; Chang, R,-S.; Lotti, V. J.; Faust, K. A.; Chen, T. B.; Schirn, T. W.; Sweet, C. S.; Emmert, S. E.; Patchett, A. A.; Greenlee, W. J. J. Med. Chem. 1991, 34, 2919 and references therein,
6. (e) Mederski, W. K. R.; Pachler, K. G. R. Tetrahedron 1992, 48, 10549.
7. (a) Duncia, J. V.; Carini, D. J.; Chiu, A. T.; Johnson, A. L.; Price, W. A.; Wong, P. C.; Wexler, R. R.; Timmermans, P. B. M. W. Med. Res. Rev. 1992, 12, 149.
8. (b) De Laszlo, S. E.; Quagliato, C. S.; Greenlee, W. J.; Patchett, A. A.; Chang, R. S. L.; Lotti, V. J.; Chen, T.-B.; Scheck, S. A.; Faust, K. A.; Kivlighn, S. S.; Schorn, T. S.; Zingaro, G. J.; Siegl, P. K. S. J. Med. Chem. 1993, 36, 3207 and references therein.
9. Curtin, M. L.; Davidsen, S. K.; Heyman, H. R.; Garland, R. B.; Sheppard, G. S.; Florjancic, A. S.; Xu, L.; Carrera, G. M.; Steinman, D. H.; Trautmann, J. A.; Albert, D. H.; Magoc, T. J.; Tapang, P.; Rhein, D. A.; Conway, R. G.; Luo, G.; Denissen, J. F.; Marsh, K. C.; Morgan, D. W.; Summers, J. B. J. Med. Chem. 1998, 41, 74.
10. Janssens, F.; Torremans, J.; Janssen, M.; Stokbroekx, R. A.; Luyckx, M.; Janssen, P. A. J. J. Med. Chem. 1985, 28, 1943.
11. Clark, R. L.; Pessolano, A. A.; Shen, T.-Y.; Jocobus, D. P.; Jones, H.; Lotti, V. J.; Flataker, L. M. J. Med. Chem. 1978, 21, 965.
12. Robinson, M. M.; Finch, N. U.S. Patent 3719683, 1973.
13. vonBebenberg, W. U.S. Patent 3819640, 1974.
14. Lesher, G. Y.; Brundage, R. P.; Opalka, C. J.; Page, D. F. French Patent 2,478,637, 1981; Chem. Abstr. 1982, 96, 85551k.
15. Kuezyński, L.; Mrozikiewiez, A.; Poreba, K. Pol. J. Pharmacol. Pharm. 1982, 34, 229.
16. Blanchi, M.; Butti, A.; Rossi, S.; Barzaghi, F.; Marcaria, V. Eur. J. Med. Chem.-Chim. Ther. 1983, 18, 501.
17. (a) Vaughn, J. R., Jr. U.S. Patent 2637731, 1953.
18. (b) Röchling, H. P. W.; Büchel, K.-H.; Korte, F. W. A. G. K. U.S. Patent 3459759, 1969.
19. Zecchini, G. P.; Torrini, I.; Paradisi, M. P. J. Heterocycl. Chem. 1985, 22, 1061.
20. Meanwell, N. A.; Sit, S. Y.; Gao, J.; Wong, H. S.; Gao, Q.; St. Laurent, D. R.; Balasubramanian, N. J. Org. Chem. 1995, 60, 1565 and references cited therein.
21. (a) Steglich, W.; Höfle, G. Angew. Chem., Int. Ed. Engl. 1969, 8, 981.
22. (b) Höfle, G.; Steglich, W. Synthesis 1972, 619.
23. (a) Kempe, R.; Arndt, P. Inorg. Chem. 1996, 35, 2644.
24. (b) Nagao, N.; Mukaida, M.; Tachiyashiki, S.; Mizumachi, K. Bull. Chem. Soc. Jpn. 1994, 67, 1802.
25. (c) Maekawa, M.; Munakata, M.; Sow, T. K.; Hachiya, K. Inorg. Chim. Acta 1994, 227, 137.
26. (d) Ranninger, M. C. N. Acta Crystallogr. 1985, C41, 21.
27. (e) Alvila, L.; Pakkanen, T. A. J. Mol. Catal. 1993, 84, 145.
28. (a) Sathyamoorthi, G.; Soong, M. L.; Ross, T. W.; Boyer, J. H. Heteroatom. Chem. 1993, 4, 603.
29. (b) Araki, K.; Mutai, T.; Shigemitsu, Y.; Yamada, M.; Nakajima, T.; Kuroda, S.; Shimao, I. J. Chem. Soc., Perkin Trans. 2 1996, 613.
30. (a) Lechat, P.; Tesleff, S.; Bowman, W. C. Aminopyridines and Similarly Acting Drugs; Pergamon Press: Oxford, NY, 1982.
31. (b) Quintela, J. M.; Peinador, C.; González, L.; Ingesias, R.; Paramá, A.; Alvarez, F.; Sanmartin, M. L.; Riguera, R. Eur. J. Med. Chem. 2003, 38, 265.
32. (c) O'Hagan, D. Nat. Prod. Rep. 2000, 17, 435.
33. (d) van Rhee, A. M.; Jiang, J.; Meman, N.; Olah, M. E.; Stiles, G. L.; Jacobson, K. A. J. Med. Chem. 1996, 39, 2980.
34. (e) Bever, C. T., Jr. CNS Rev. 1995, 1, 261.
35. (a) Wagaw, S.; Buchwald, S. L. J. Org. Chem. 1996, 61, 7240.
36. (b) Muci, A. R.; Buchwald, S. L. Top. Curr. Chem. 2002, 219, 131 and references therein.
37. (a) Maes, B. U. W.; Loones, K. T. J.; Jonckers, T. H. M.; Lemiére, G. L. F.; Dommisse, R. A. Synlett 2002, 1995.
38. (b) Jonckers, T. H. M.; Maes, B. U. W.; Lemiére, G. L. F.; Dommisse, R. A. Tetrahedron 2001, 57, 7027.
39. Ji, J.; Bunnelle, W. H. Org. Lett. 2003, 5, 4611.
40. (a) Vorbruggen, H. Advances in Heterocyclic Chemistry; Academic Press: San Diego, CA, 1990; Vol. 49, pp 117-192.
41. (b) Gupton, J. T.; Idoux, J. P.; Baker, G.; Colon, C.; Crews, A. D.; Jurss, C. D.; Rampi, R. C. J. Org. Chem. 1983, 48, 2933.
42. (c) Pedersen, E. B.; Carlsen, D. Synthesis 1978, 844.
43. (d) Patel, K. M.; Sparrow, J. T. Synth. Commun. 1979, 9, 251.
44. (e) Vorbruggen, H. Synthesis 1973, 301.
45. Sakamoto, T.; Kondo, Y.; Yamanaka, H. Chem. Pharm. Bull. 1985, 33, 4764. For an improved procedure describing the preparation of 4 see the Supporting Information.
46. The use of triethylamine has been shown to provide significant rate enhancement in palladium-catalyzed animations of aryl iodides when cesium carbonate is employed as the base. For a leading reference see: Ali, M. H.; Buchwald, S. L. J. Org. Chem. 2001, 66, 2560.
47. In certain cases where the reaction product was used crude, minor amounts of unreacted starting materials were present. The presence of these impurities had no detrimental affect on the outcome of subsequent transformations.
48. Unsubstituted pyrido[2,3-b]pyrazinediones have been shown to possess antagonistic activity at the glycine site on the N-methyl-D-aspartate (NMDA) receptor which has been implicated in several neurodegenerative disorders such as Alzheimer's diesease, epilepsy, and stroke. For a leading reference, see: Cugola, A.; Donati, D.; Guarneri, M.; Micheli, F.; Missio, A.; Pecunioso, A.; Reggiani, A.; Tarzia, G.; Zanirato, V. Bioorg., Med. Chem. Lett. 1996, 6, 2749 and references therein.